Editas Medicine (NASDAQ:EDIT)

CAPS Rating: 5 out of 5

EDIT News and Commentary

Caps

How do you think EDIT will perform against the market?

Add Stock to CAPS Watchlist

All Players

201 Outperform
7 Underperform
 

All-Star Players

80 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top EDIT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFRendezvous (82.92)
Submitted December 17, 2017

The genetic medicine field is unquestionably the future. There are a handful of "CRISPR gene editing" public biotechs, which I conveniently found on StockTwits. Was interested in it when RB made it a rec as it fits into one of my favorite long term… More

btechrisk11 (< 20)
Submitted April 15, 2018

Still a lot to learn for CRISPR technology to translate to clinic safely. CRISPR can be fairly selective but there was a recent journal article suggesting many people have antibodies/immune responses against some of the CRISPR elements.

EDIT VS S&P 500 (SPY)

EDIT Summary

Fools bullish on EDIT are also bullish on:

Fools bearish on EDIT are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EDIT.

Recs

0
Member Avatar mfoolid (49.00) Submitted: 8/10/2018 1:12:52 PM : Outperform Start Price: $29.57 EDIT Score: -1.09

RB Rec

Recs

0
Member Avatar TrevorCarson (< 20) Submitted: 6/2/2018 3:26:52 PM : Outperform Start Price: $37.10 EDIT Score: -24.29

Paladin pick

Recs

2
Member Avatar btechrisk11 (< 20) Submitted: 4/15/2018 3:31:17 PM : Underperform Start Price: $34.93 EDIT Score: +22.31

Still a lot to learn for CRISPR technology to translate to clinic safely. CRISPR can be fairly selective but there was a recent journal article suggesting many people have antibodies/immune responses against some of the CRISPR elements.

Leaderboard

Find the members with the highest scoring picks in EDIT.

Score Leader

PAGEBOY73

PAGEBOY73 (98.84) Score: +120.59

The Score Leader is the player with the highest score across all their picks in EDIT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
SeriousK 29.15 3/9/2016 Underperform 5Y $42.70 -31.92% +41.34% +73.26 0 Comment
freemarketmike < 20 6/7/2017 Outperform 5Y $15.43 +88.36% +15.70% +72.66 1 Comment
WoollyWombat < 20 9/16/2016 Outperform 5Y $14.48 +100.76% +32.07% +68.69 0 Comment
portefeuille 98.45 2/10/2016 Outperform 5Y $13.26 +119.23% +51.11% +68.12 0 Comment
FunesDMemorious 98.01 10/26/2016 Outperform 5Y $14.55 +99.79% +32.16% +67.63 0 Comment
CMFMLove 35.27 6/13/2017 Outperform 5Y $16.00 +81.69% +15.49% +66.19 1 Comment
portefeuille2 99.22 9/22/2016 Outperform 5Y $14.87 +95.49% +29.87% +65.62 0 Comment
Playa14 < 20 6/9/2017 Outperform 5Y $16.08 +80.78% +15.44% +65.34 0 Comment
forcel0 93.67 11/23/2016 Outperform 5Y $15.60 +86.35% +28.06% +58.29 0 Comment
hayrettin 70.97 7/28/2017 Outperform 5Y $16.96 +71.40% +14.23% +57.17 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EDIT.

Featured Broker Partners


Advertisement